Any current/future new fundraising through debt or equity?

Current Debt: Around INR 375 crores (term loan for Indore plant + working capital loans). Debt Level Outlook: Expected to remain at INR 375 crores through FY '27. Deleveraging Plan: No prepayment of term loan until after FY '27; prepayment will start from FY '28 onwards. Working Capital: Managed largely through internal accruals rather than additional borrowing. No mention of new equity fundraising or additional debt plans in the near term. Focus is on internal cash flow and operational efficiencies rather than fresh fundraising for the next 2-3 years.

Future growth expectations in sales/revenue/volumes?

The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors. International business (exports) is expected to ramp up notably from Q2/Q3 FY 2026 with the completion of audits and approvals (e.g., EU GMP certificate by March/April 2026). The Indore plant ramp-up will contribute significantly, with production utilization projected to hit 50% by Q4 FY 2026-27 and further growth thereafter. Export revenues from Indore are expected to start materializing in Q3/Q4 FY 202

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '27 revenue growth targeted at a **minimum of 15%**, with potential to reach **20% or more** depending on regulatory approvals and market factors (Page 14, 6). EBITDA from the Indore plant expected to break even by **Q4 FY '25-'26** and become cash flow positive post FY '27 (Page 11). Export revenues from Indore anticipated to start significantly contributing from **Q3/Q4 FY '26** with EU GMP and other regulatory approvals (Page 11, 6). Debt levels expected to stay around **INR 375 crores till March '27**, then begin to reduce with term loan prepayment starting FY '28 (Page 16). Operating e

Current/ Expected Orderbook/ Pending Orders?

The current order book at Indore (Unit-2) stands at around INR150 crores to INR155 crores. Management aims to reduce this order book to around INR80 crores to INR90 crores. The reduction target is to bring the order book from a 90-day window to a 60-day window. Navsari orders for exports to countries like the U.K., Portugal, and Brazil are also ramping up. The export division has shown growth of approximately 40%, though the base is smaller (~INR120 crores). Validation batches for GLP-1 products from Indore were completed in January, with testing ongoing in February. Overall, there is a positi

IN US

Sale is live|00:00:00left today

Gufic BioSciences LtdQ4 FY27Pharmaceuticals & Biotechnology

Gufic BioSciences Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹368P/E: 56.5Market Cap: ₹2.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors.
→International business (exports) is expected to ramp up notably from Q2/Q3 FY 2026 with the completion of audits and approvals (e.g., EU GMP certificate by March/April 2026).
→The Indore plant ramp-up will contribute significantly, with production utilization projected to hit 50% by Q4 FY 2026-27 and further growth thereafter.
→Export revenues from Indore are expected to start materializing in Q3/Q4 FY 2026, especially across Europe, Southeast Asia, and regulated markets.
→Domestic branded business growth is seen around 8% due to correction in debtor control and divestment in certain divisions.
→Botulinum toxin segment is growing strongly (22-25% YoY) with potential for further category expansion.
→EBITDA margins are expected to improve with increasing capacity utilization, reaching up to 20-21% beyond 75% utilization.

Margin guidance

Category 2

→FY '27 revenue growth targeted at a **minimum of 15%**, with potential to reach **20% or more** depending on regulatory approvals and market factors (Page 14, 6).
→EBITDA from the Indore plant expected to break even by **Q4 FY '25-'26** and become cash flow positive post FY '27 (Page 11).
→Export revenues from Indore anticipated to start significantly contributing from **Q3/Q4 FY '26** with EU GMP and other regulatory approvals (Page 11, 6).
→Debt levels expected to stay around **INR 375 crores till March '27**, then begin to reduce with term loan prepayment starting FY '28 (Page 16).
→Operating expenses, including employee costs, projected to rise moderately due to increments but stabilize post-ramp-up (Page 7).
→Margins likely to maintain with stable depreciation/interest costs (~INR35-36 crores) in FY '27 (Page 16).
→Overall outlook is cautious but optimistic, factoring in working capital control and regulatory uncertainties.

3 more insights locked — sign up free to unlock

Fundraise plans

→Current Debt: Around INR 375 crores (term loan for Indore plant + working capital loans).
→Debt Level Outlook: Expected to remain at INR 375 crores through FY '27.
→Deleveraging Plan: No prepayment of term loan until after FY '27; prepayment will start from FY '28 onwards.
→Working Capital: Managed largely through internal accruals rather than additional borrowing.
→No mention of new equity fundraising or additional debt plans in the near term.
→Focus is on internal cash flow and operational efficiencies rather than fresh fundraising for the next 2-3 years.

Order book

Yes

→The current order book at Indore (Unit-2) stands at around INR150 crores to INR155 crores.
→Management aims to reduce this order book to around INR80 crores to INR90 crores.
→The reduction target is to bring the order book from a 90-day window to a 60-day window.
→Navsari orders for exports to countries like the U.K., Portugal, and Brazil are also ramping up.
→The export division has shown growth of approximately 40%, though the base is smaller (~INR120 crores).
→Validation batches for GLP-1 products from Indore were completed in January, with testing ongoing in February.
→Overall, there is a positive outlook on the order inflow and its impact on revenue going forward.

Capex plans

Yes

- Investment in Selvax, a cancer vaccine therapy for solid tumors, with over $150,000 invested over the last 4-5 years; this is a long-term, start-up-like investment with promising animal-level proof of concept and ongoing progress such as outsourcing final construct to Syngene. - Indore plant expansion with term loans taken for capacity ramp-up; expected to reach 50% utilization by Q4 FY '26-'27 and contribute to export revenue starting Q3/Q4 FY '26. - Investments in technology transfer projects like GLP-1 validation batches at Indore, enhancing production capabilities. - Implementation of Marg software in stockists to strengthen data control and optimize working capital. - No fresh major recruitments planned; focus on annual increments and productivity improvements. - Ongoing R&D and validation expenses as recurring costs for at least 1.5 to 2 years associated with product and regulatory development. Overall, capex focus is on capacity expansion, strategic long-term biotech investments, and digital infrastructure for sales and working capital management.

How does Gufic BioSciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Gufic BioSciences Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Gufic BioSciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio